SAN FRANCISCO, Jan 10 – Celera Genomics on Wednesday announced moves that signal the beginning of the company's foray into the drug target discovery sector.

"We are looking to identify new drug targets," Peter Chambre, Celera’s chief operating officer, said at a company presentation at the JP Morgan H&Q conference.

As part of that move, Celera also announced on Wednesday that it had hired Stephen Hoffman, a pioneer in the development of DNA vaccines, as its senior vice president of immunotherapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.